1. All PIR are required to register at the CSU Rx general office upon arrival and departure from the hospital, including any building on the VHHSC grounds. Registration will include written documentation of date/time, name, affiliation, contact person or persons at hospital and intent (including drugs(s) to be detailed).
2. Upon registration, an identification tag will be provided which the representative must wear in a highly visible location and at all time while on hospital grounds. This tag must be returned to the CSU Rx general office prior to leaving the hospital grounds.
3. Activities of the PIR are restricted to office and meeting room areas of the hospital only. Under no circumstances are representatives permitted to carry on any activities in patient care areas.
4. Industry preceptorships or any other type of similar activity involving PIR must not be carried out in any patient care area, nor should these activities involve any direct patient contact.
5. Only medical, pharmacy and purchasing staff may be detailed about drug products.
6. Appointments with physicians, pharmacists and purchasing staff must be arranged with these individuals directly and take place in an office area. Where the office is located inside a clinical area of the hospital, the visit must not intrude on the clinical activity of the area, and the hospital claims no responsibility for the safety of the PIR.
7. Educational or promotional material must not be posted or displayed in the hospital.
8. Promotion of products on the drug formulary and those that have not been reviewed by the Drugs and Therapeutics Committee is permitted, but any promotion of drugs that are not listed in the formulary must include notification of that fact. Products that have been denied by the Committee or deleted from the formulary are not to be promoted within the hospital.
9. Requests for addition of a drug to the VH&HSC Formulary must be made by physicians by contacting the CSU Pharmaceutical Sciences general office.
10. Copies of all promotional or other drug literature that is intended for distribution to any health care professional must be provided to the CSU Pharmaceutical Sciences general office prior to dissemination.
11. Drug samples must not be distributed to hospital personnel for patient use. Under no circumstances are samples to be left in any patient care area of the hospital.
12. Pharmaceutical displays are not permitted in any area of the hospital.
13. Copies of medical staff lists are intended for the use of hospital staff only, and will not be made available to PIR.
14. All PIR shall be advised that their company's participation in industry-funded research is unrelated to formulary decisions made within this institution.
15. Hospital communication systems (i.e. intercom systems) must not be used by PIR to locate hospital personnel. Hospital pagers can be used to contact hospital personnel only if previously approved by that individual.

These guidelines will be distributed to all PIR. To maximize compliance with the proposed guidelines, medical and pharmacy personnel will monitor PIR activities. Where PIR have been identified as having violated hospital visitation privileges, the individual will be contacted by the Director of CSU Rx (or delegate) to reinforce the guidelines. A second violation of the guidelines will result in written communication between the Director and the company's regional manager (or equivalent). At the discretion of the Director, contact may be made with Canada's Research-Based Pharmaceutical Companies (previously designated the Pharmaceutical Manufacturers Association of Canada (PMAC)) to alert them that a violation of the hospital regulation and their Code of Marketing has occurred. In this correspondence, the company will be notified that the PIR is on report. A third violation will result in loss of hospital visitation privileges by that PIR for a minimum of six months.